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lation (AF). It is therefore relevant to evaluate NOACs relative cost-effectiveness 
in Portuguese AF patients. Methods: A Markov model was used to analyze the 
disease progression over a lifetime horizon. Relative efficacy data for stroke 
(ischemic and hemorrhagic), bleeding (intracranial, other major bleeds and clini-
cally relevant non-major bleeds), myocardial infarction and treatment discontinu-
ation were used by means of pairwise indirect treatment comparisons between 
apixaban, dabigatran and rivaroxaban using warfarin as a common comparator. 
Resource use was obtained from Diagnosis Related Group legislation data base and 
an expert panel. Model outputs included life years gained, quality-adjusted life 
years (QALYs), direct healthcare costs and incremental cost-effectiveness ratios 
(ICERs). Results: Apixaban provided the highest life years gained and QALYs. The 
apixaban ICER versus warfarin and dabigatran was 5,529€ /QALY and 9,163€ /QALY, 
respectively. Apixaban was dominant versus rivaroxaban (higher health gains and 
lower costs). Results were robust over a wide range of inputs in sensitivity analy-
ses. Apixaban had a 70% chance of being cost-effective (at a threshold of 20,000€ /
QALY) versus the set of all other therapeutic options. ConClusions: Apixaban 
is a cost-effective alternative to warfarin and dabigatran and is dominant versus 
rivaroxaban in AF patients from a Portuguese national healthcare system perspec-
tive. These conclusions are based on indirect treatment comparisons. Despite 
this limitation, this information is relevant for different health care decision 
makers.
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objeCtives: Dabigatran was proven to have similar effect on the recurrence of 
venous thromboembolism (VTE) and a lower risk of bleeding compared to vita-
min K antagonists (VKAs). This study aims to assess the cost-effectiveness (CE) 
of dabigatran for the treatment and secondary prevention in high risk patients 
of VTE compared to VKAs in the Dutch setting. Methods: Previously published 
Markov model was modified and updated to assess the CE of dabigatran and VKAs 
for the treatment and secondary prevention in high risk patients of VTE from a 
societal perspective in the base-case analysis. The model was populated with 
efficacy and safety data from major dabigatran trials (i.e. RE-COVER, RECOVER II, 
RE-MEDY and RE-SONATE), Dutch specific costs, and utilities derived from dabi-
gatran trials or other published literature. Univariate, probabilistic sensitivity 
and a number of scenario analyses on the impact of various decision-analytic 
settings (e.g. the perspective of analysis, use of anticoagulants only for treat-
ment or only for secondary prevention) were tested on the incremental cost-
effectiveness ratio (ICER). Results: In the base-case, patients on dabigatran 
gained an additional 0.583 discounted quality adjusted life years (QALYs) over 
a lifetime and savings of € 1,996. Results of univariate sensitivity analysis were 
quite robust. The probability that dabigatran is cost-effective at a willingness-
to-pay threshold of € 20,000/QALY was 100%. Except for the scenario comparing 
dabigatran to VKAs from the healthcare provider perspective and the one com-
paring dabigatran to placebo for the prevention of recurrent VTE in patients who 
are at equipoise for anticoagulation treatment where the ICERs for dabigatran 
compared to VKAs of € 1,005 and € 33,305 per QALY gained, respectively were esti-
mated, other scenarios showed dabigatran was cost-saving. ConClusions: From 
a societal perspective, dabigatran is likely to be a cost-effective or even cost-saving 
strategy for treatment and secondary prevention of VTE compared to VKAs in the 
Netherlands.
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objeCtives: To estimate the health benefits and cost-effectiveness of a polypill 
intervention (100mg aspirin, 20mg atorvastatin and 10mg ramipril) for the second-
ary prevention of cardiovascular (CV) events in adults with a history of myocardial 
infarction (MI) from the perspective of the Spanish health system compared with 
multiple monotherapy. Methods: A Markov model was developed to estimate 
health outcomes, costs and incremental cost-effectiveness ratio (ICER) per LY 
gained and per QALY gained using a 10-year time horizon. The patient population 
included were men and women with an average age of 64.7 years, a history of 
MI and an indication for secondary prevention treatment. Patients in the model 
have a 3-month probability cycle to have one of the following five CV events: acute 
coronary syndrome, non-fatal stroke, non-fatal congestive heart failure requir-
ing hospitalization, unplanned revascularization procedures, or (non-)CV death. 
Model inputs on efficacy, utility and adherence were obtained from systematic 
reviews. Different scenarios were modelled using different sources for acute event 
costs and alternative prices for polypill and its monocomponents. Probabilistic 
analyses were performed to test the robustness of the results. Results: Polypill 
showed to prevent 45 CV fatal and non-fatal events per 1,000 patients in Spain 
in the base case. Total LYs and QALYs gained were 38 and 36 respectively, show-
ing polypill was the dominant strategy. Probabilistic sensitivity analyses for the 
base-case assumptions showed a 90.1% chance of the polypill being cost-effec-
tive at a willingness-to-pay threshold of € 30,000 per QALY gained compared with 
multiple monotherapy. Alternative scenario analyses showed that the polyp-
ill resulted to be dominant or cost-effective in all scenarios. ConClusions: 
The polypill intervention appears to be the dominant or cost-effective strategy 
versus its monocomponents taken separately, showing it can prevent fatal and 
non-fatal CV events in the Spanish population as well as to reduce healthcare 
costs.
A pharmacoeconomic model of administering actovegin in female patients with 
chronic venous disease of lower extremities was developed on the basis of clini-
cal data (Uchkin IG et al.). Three strategies of complex therapy were considered in 
three groups of 100 patients each: 1st group — standard management, 2nd group 
— standard management + local actovegin, 3rd group — standard management + 
both intravenous and local actovegin. Criteria of efficiency were defined as removal 
of heavy legs syndrome and wound healing. Costs of drug administration, hospi-
talization and lab tests were under consideration. The time horizon equalled 1 
month. Results: We determined costs of patient management for each of the 
groups. The costs constituted 8 732 092,50 RUB in the 1st group, 8 543 937,88 RUB in 
the 2nd group, and 8 860 710,75 RUB in the 3rd group, so they did not vary consider-
ably. The cost effectiveness for the removal of heavy legs syndrome in the standard 
therapy group was equal to 14 895,97, while it constituted 10 744,87 and 11 826,97 
in the second and third groups, respectively. CER values considering the number 
of patients with wound healing were 39 482,20 for the 1st group, and 26 889,65 and 
15 689,74 for the 2nd and 3rd groups, respectively. ConClusions: Actovegin in 
complex therapy of complicated chronic venous disease of lower extremities is 
substantiated from the pharmacoeconomic standpoint of cost effectiveness ratio.
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objeCtives: Acute coronary syndrome is a “vehicle diagnosis”, the ambulance 
service and involves unstable angina, myocardial infarction, including – without 
segment elevation of ST segment. Aim of this study was to conduct clinical and 
economic analysis of application of fondaparinux sodium and enoxaparin sodium 
in the treatment of acute coronary syndrome. Methods: The method of modeling 
with decision-tree model and “cost-effectiveness” ratio were used. Endpoints were: 
mortality, the onset of myocardial infarction in the 9th, 30th and 180th day from 
the start of the study regarding the side effects in patients with acute coronary 
syndrome based on the results of clinical trials OASIS-5. Calculating the cost of drugs 
and medical services was conducted according to experts and standard of medi-
cal care. Results: The cost of treatment of a single patient with acute coronary 
syndrome with fondaparinux sodium were lower compared with enoxaparin 
sodium to 9th, 30th and 180th day of treatment at 38 € , 42 € and 36 € , respectively. 
The cost-effectiveness ratio on the criterion of “the likelihood of myocardial infarc-
tion” for fondaparinux and enoxaparin on the 9th day of treatment was 5210 € and 
6641 € , on the 30th day - 4084 € and 4810 € , on the 180th day - 3396 € and 3939 € , 
respectively. The cost-effectiveness ratio on the criterion “probability of death” for 
fondaparinux and enoxaparin on the 9th day of treatment was 7525 € and 9088 € , 
on the 30th day - 5351 € and 5635 € , on the 180th day - 3839 € and 4171 € , respec-
tively. ConClusions: The use of fondaparinux sodium is the dominant technology 
in myocardial infarction without lifting ST segment, other direct anticoagulants are 
assigned only in case of its absence.
PCV111
the CoSt-eFFeCtiVeneSS oF bariatriC Surgery in germany
Belarbi S1, Kusel J2, Maruszczak M2, Slater D2, Thomas MG2, Martini O3
1Ethicon SAS, Issy-Les-Moulineaux, France, 2Costello Medical Consulting Ltd, Cambridge, UK, 
3Ethicon, part of Johnson & Johnson Medical GmbH, Norderstedt, Germany
objeCtives: Patients eligible for bariatric surgery in Germany often do not receive 
this treatment, and sometimes receive no medical care for their obesity at all as 
the conventional care (CC) of behaviour/activity programmes are not reimbursed 
by the sickness funds. Methods: We developed a Markov model to estimate the 
long-term (20 year) outcomes and costs for patients who receive bariatric surgery 
(gastric bypass or sleeve gastrectomy), CC, or no care (NC), from a German health-
care perspective. Body mass index (BMI) change, type II diabetes mellitus (T2DM), 
stroke, myocardial infarction and cancer were all included; inputs for these were 
taken from recent network meta-analyses. Utilities and costs were sourced from 
the literature and the German DRG tariff. It was assumed that NC patients had 
no obesity care costs and remained at baseline BMI, blood pressure and choles-
terol level. The populations considered were patients with BMI≥ 40 or BMI≥ 35 with 
obesity-related comorbidities, and the subpopulation of T2DM patients. Costs and 
outcomes were discounted at 3% yearly. Results: Compared to those receiving CC 
and NC, patients undergoing bariatric surgery were found to live longer and have 
fewer cases of stroke (-11 and -9 cases per 1000 patients, respectively), myocardial 
infarction (-35 and -41 cases per 1000 patients, respectively) and cancer (-17 cases 
per 1000 patients for both). The difference between bariatric surgery patients and 
CC or NC was even greater in patients with T2DM. Bariatric surgery was found to 
have an ICER of € 361 per QALY versus CC (incremental cost € 921, QALY gain 2.55) 
and of € 812 per QALY versus NC (incremental cost € 2055, QALY gain 2.53). Bariatric 
surgery was associated with an ICER of less than € 10,000/QALY in 100% of simula-
tions versus both CC and NC. ConClusions: Bariatric surgery improves patient 
outcomes and is cost-effective in Germany compared to conventional or no care.
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objeCtives: Recently, three novel non-vitamin K antagonist oral anticoagulants 
(NOACs) got reimbursed in Portugal for patients with non-valvular atrial fibril-
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analysis was to develop two cost effectiveness models taking into account the 
new management of the treatment of AF and VTE in France. The clinical and cost 
benefits of VKA (with/without the use of a PAS) has been evaluated versus new 
oral anticoagulants (NOAC): dabigatran, rivaroxaban and apixaban. Methods: 
A Markov model was built for the treatment of AF and a decision tree for the 
treatment and prevention of VTE. In the VKA arms, both models integrate the pos-
sibility to adjust the percentage of time spent by patients within INR therapeutic 
range. In the VTE model, outcomes were expressed in cost per avoided event 
whereas in the AF model in cost per QALY. Results: In both models, apixaban is 
the strategy producing the least thromboembolic and hemorrhagic events whereas 
AVK strategies are the cheapest treatments (2 to 2.5 times less than NOAC treat-
ments). The use of the software for the treatment and prevention of VTE allows 
to save € 3,192 per avoided event and for the AF treatment € 7,557 per extra QALY 
gained and € 6,688 per avoided event. ConClusions: Based on French guide-
lines for economic evaluation, apixaban and VKA + PAS are efficient strategies 
in AF.
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objeCtives: As new therapies for chronic heart failure with reduced ejection 
fraction (HFrEF) emerge, health technology assessments (HTAs) will require cost-
effectiveness analyses to inform decision making. The objective was to develop 
a model framework for evaluating the cost-effectiveness of LCZ696, a novel oral 
therapy proposed for the treatment of HFrEF. Methods: A systematic literature 
review was performed. Searches were conducted in MEDLINE, EMBASE, EconLit, and 
Cochrane Library databases, with supplementary hand searching of conferences and 
HTA websites. Of 63 distinct analyses identified, 33 used decision-analytic models. 
Structures were most commonly described as Markov models (n= 27), but meth-
ods employed were heterogeneous. The health states most frequently employed 
were ‘alive’ and ‘dead’, with outcomes such as hospitalization or New York Heart 
Association (NYHA) class distribution most commonly considered within the ‘alive’ 
state. Results: A 2-state Markov model with ‘alive’ and ‘dead’ states was developed 
using three multivariate regression models to predict the risks of mortality, hospi-
talisation and the trajectory of health-related quality of life over time within the 
‘alive’ state. NYHA class was not used as a basis for health states, as the extrapola-
tion of clinical improvements beyond the observed data was considered clinically 
implausible. Parametric survival models, negative binomial models and multilevel 
models are used to predict mortality, hospitalisation, and HRQL, respectively, allow-
ing extrapolation to a lifetime time horizon. The model of HRQL attempts to cap-
ture the effects of baseline characteristics, hospitalisation, adverse events and time 
on EQ-5D. Clinical experts were consulted to validate the regression models and 
their respective predictions. ConClusions: The new framework employs similar 
methods to decision analytic models developed previously in heart failure, however 
models health-related quality of life as a function of time directly, thereby providing 
a parsimonious approach with improved clinical plausibility compared to other 
model structures in the literature.
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objeCtives: Venous thromboembolism (VTE) which comprises deep vein throm-
bosis (DVT) and pulmonary embolism (PE) is associated with a significant health-
care burden. Currently, the standard of care is parenteral low molecular weight 
heparin (enoxaparin) plus warfarin. Rivaroxaban is an oral anticoagulant that 
does not require dose adjustment or routine coagulation monitoring, bringing 
an important advantage for the treatment of VTE. The EINSTEIN clinical pro-
gram of rivaroxaban showed that, overall, hospitalized patients who received 
initial treatment with rivaroxaban for DVT and PE had a significantly shorter 
length of stay compared to patients who received enoxaparin/VKA. Therefore, 
the aim of this study was to compare the direct costs of treatment with rivar-
oxaban versus enoxaparin/warfarin. Methods: A cost-minimization analysis 
(CMA) was chosen once the EINSTEN program showed that rivaroxaban is non-
inferior to enoxaparin/VKA with regards to efficacy for treatment of VTE being 
possible to consider that there is no difference in outcomes. Perspective was 
from the Brazilian private healthcare system and time horizon was one year. 
Costs related to hospitalization, outpatient management and adverse events 
were obtained by micro-costing approach and resource use captured from lit-
erature and expert panel. Costs were expressed in 2015 prices and exchange rate 
used was $1.00USD= 3.00BRL. Results: Rivaroxaban use resulted less expen-
sive than enoxaparin+warfarin in the treatment of VTE. Estimated total cost of 
treatment for one patient with VTE is $2,079 with rivaroxaban and $2,716 with 
enoxaparin+warfarin. The greater difference in costs was for treatment of PE, which 
was $688.57 less for rivaroxaban. For DVT treatment, estimated savings for rivar-
oxaban was $561.46. Robustness of the model was tested in a deterministic univar-
iate sensitivity analysis in which all results remained cost saving. ConClusions: 
Rivaroxaban is a cost-saving alternative compared to the current practice for 
the treatment of VTE under the perspective of the Brazilian private healthcare 
system.
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objeCtives: In-situ tissue-engineering provides a promising method to cre-
ate living heart valves with the potential to grow, repair and last a lifetime. The 
objective of the present study is to develop a conceptual model (CM) that can be 
used to investigate the requirements for tissue-engineered heart valves (TEHV) to 
become cost-effective compared to current surgical and transcatheter heart valve 
substitutes (HVS). Methods: The development of the CM was based on recom-
mendations from the ISPOR-SMDM Modeling Good Research Practices Task Force-2. 
After scoping the decision problem, a draft CM was developed based on clinical 
guidelines and discussion within a small workgroup. This model was compared 
with existing models for cost-effectiveness of HVS, found by systematic literature 
search. It was further discussed with a Delphi panel of cardio-thoracic surgeons, 
cardiologists and a biomedical scientist (n= 10). Delphi panelists were first inter-
viewed individually to discuss the CM structure. Thereafter, they completed online 
surveys in order to reach consensus between panelists. Results: Health states 
included in the CM are ‘alive without complications’, cerebrovascular accident, 
myocardial infarction, vascular complication, bleeding, acute kidney injury, atrial 
fibrillation, pacemaker implantation, prosthetic valve dysfunction, prosthetic 
valve thrombosis, prosthetic valve endocarditis, ‘alive after complications’ and 
dead. Predictors of transition probabilities between the health states are included; 
age, gender, NYHA functional class, left ventricular function, renal impairment, 
and diabetes. Relevant outcome measures included health-related quality of 
life, event occurrence, event-free survival, mortality and costs. ConClusions: 
The CM provides the foundation of a microsimulation model that will be used 
to estimate the cost-effectiveness of TEHV compared with current HVS. The 
results will be used to inform stakeholders about the requirements for TEHV to 
become cost-effective. This information can help bio-tech companies to decide 
about further development of TEHV, focus on the most promising target groups, 
set realistic performance-price goals, and design and manage a reimbursement 
strategy.
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objeCtives: The World Health Organization guidelines recommend that an 
increase of potassium intake reduce blood pressure in adults. In addition, inter-
vention with vitamin B2 has been shown to lower blood pressure in patients with 
genotype, specifically in hypertensive patients with premature cardiovascular dis-
ease (CVD) homozygous for the 677C→ T polymorphism (TT genotype) in the gene 
encoding for the enzyme methylenetetrahydrofolate reductase. In the Chinese 
northern region, the prevalence of this TT genotype was estimated to be 35% of the 
population. Furthermore, 26% of adults are hypertensive and 20% adults will experi-
ence a CVD episode.This study aims to evaluate the impact of increased intake of 
potassium and vitamin B2 have on blood pressure, CVD events and quality-of-life 
among Chinese adults older than 45 years old. Furthermore this study assesses the 
costs and cost-effectiveness of achieving this impact via the consumption of a forti-
fied milk product. Methods: An analytical decision model was used to quantify 
and compare three strategies against the current intake of the at-risk-population: 1) 
Increased potassium intake level 2) Increased vitamin B2 intake level 3) Combined 
increased vitamin B2 and potassium intake levels. The effectiveness of these strate-
gies in incrementing vitamin B2 and potassium were determined by patient level 
data and the Framingham methodology. All costs and epidemiological data were 
collected from the literature. Results: All strategies led to statistically significant 
health outcomes due to the preventive effect of increased intake of potassium and 
vitamin B2 also resulting in a significant Quality Adjusted Life Years gain over the 
baseline. Each strategy is shown to be cost-effective or highly cost-effective with 
the largest effect being the combined increased intake of potassium and vitamin 
B2. ConClusions: The strategy of the combined increased intake of vitamin B2 
and potassium is highly cost-effective thereby preventing CVD events and saving 
costs to the health system.
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objeCtives: Vitamin K Antagonist (VKA) have traditionally been the main treat-
ment for thromboembolic event prevention in atrial fibrillation (AF) and for the 
treatment of venous and pulmonary thromboembolic events (VTE) and the pre-
vention of their relapses. A close patient monitoring with the determination of 
the INR (International Normalized Ratio) is needed during the AVK treatment, to 
avoid adverse thrombotic or hemorrhagic events. The improvement of the time 
spent in the therapeutic range (TTR), depending on INR results, has previously 
been studied in France with the use of a prescription assistance software (PAS). 
The use of this PAS improves the TTR from 58.46% to 71.79%. The objective of the 
